冯静,潘竟,陈源,张俐,吴春陶,贺星茗

• 1:成都市公共卫生临床医疗中心

摘要(Abstract)：

目的 系统评价HIV感染者使用长效抗反转录病毒药物治疗（LA-ART）真实体验的质性研究。方法 系统检索国内外数据库收录的关于HIV感染者使用LA-ART的质性研究，检索时间为建库至2025年5月。采用JBI循证卫生保健中心质性研究文献质量评价标准评价纳入文献质量，采用汇集性整合方法对结果进行整合。结果 共纳入16篇文章，提取63个主题，归纳为9个类别，形成3个整合结果：HIV感染者使用LA-ART的促进因素：包含减轻每日服药负担、提升用药便捷性，舒缓心理压力、缓解自我污名化，保护个人隐私、降低信息暴露风险；HIV感染者使用LA-ART的障碍因素：涉及患者对治疗效果的主观疑虑、药物不良反应与长期安全性顾虑、注射给药引发的生活适配问题、治疗费用偏高与药物可及性不足；HIV感染者对LA-ART方案的偏好：表现为患者渴求医患间充分信任与诊疗信息透明化，同时将灵活化、个体化的医疗服务模式作为长期维持用药的重要需求。结论 HIV感染者接受LAART同时存在获益体验与多重使用障碍，并对医患沟通、随访管理有着明确服务诉求。临床可依托LA-ART自身优势落实健康宣教，精准消解疗效、用药安全、经济层面的应用难题；结合患者需求优化沟通及随访体系，优化治疗体验，提升用药依从性与病毒抑制水平，改善感染者生存质量。

关键词(KeyWords)： 人类免疫缺陷病毒;长效抗反转录病毒治疗;质性研究;Meta整合

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 冯静,潘竟,陈源,张俐,吴春陶,贺星茗

DOI: 10.13419/j.cnki.aids.2026.10.21

参考文献(References)：

• [1]卢珍珍，姜晨晨，倪明健，等.中国艾滋病高效抗病毒治疗研究进展[J].中国公共卫生，2020, 36(4):639-642. DOI:10.11847/zgggws1125584.
• [2]刘富.艾滋病药物治疗管理的研究进展[J].北方药学，2024,21(2):193-196.
• [3]Kanazawa JT, Saberi P, Sauceda JA, et al. The LAIs are coming! implementation science considerations for long-acting injectable antiretroviral therapy in the United States:a scoping review[J]. AIDS Res Hum Retroviruses, 2021, 37(2):75-88.DOI:10.1089/AID.2020.0126.
• [4]胡雁.如何开展质性研究的系统评价和Meta整合[J].上海护理，2020, 20(7):1-5. DOI:10.3969/j. issn. 1009-8399.2020.07.001.
• [5]Garris C, Kolobova I, Chounta V, et al. Qualitative evaluation of survey questions to assess treatment preference for daily oral or long-acting injectable antiretroviral therapy among people living with HIV[J]. PLoS One, 2024, 19(12):e0309588.DOI:10.1371/journal.pone.0309588.
• [6]Fletcher L, Burrowes SAB, Khan GK, et al. Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site:a qualitative study of people with HIV experiencing substance use and/or housing instability[J]. Harm Reduct J,2023, 20:4. DOI:10.1186/s12954-023-00730-z.
• [7]Carillon S, Gallardo L, Linard F, et al. Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention:understanding potential users’ ambivalences[J].AIDS Care, 2020, 32(sup2):155-161. DOI:10.1080/09540121.2020.1742869.
• [8]Collins AB, Macon EC, Langdon K, et al. Perceptions of longacting injectable antiretroviral therapy among people living with HIV who use drugs and service providers:a qualitative analysis in rhode island[J]. J Urban Health, 2023, 100(5):1062-1073.DOI:10.1007/s11524-023-00755-6.
• [9]Hassan SA, Munyoro D, Maju M, et al. Perceived benefits and barriers to the use of long-acting injectable antiretroviral treatment among adolescents and young people living with HIV in Western Kenya:qualitative findings from the KuwaFree!LiveFree! Study[J]. Front Med, 2025, 12:1518719. DOI:10.3389/fmed.2025.1518719.
• [10]Zakumumpa H, Alinaitwe A, Kyomuhendo M, et al. Longacting injectable antiretroviral treatment:experiences of people with HIV and their healthcare providers in Uganda[J]. BMC Infect Dis, 2024, 24(1):876. DOI:10.1186/s12879-024-09748-5.
• [11]Simoni JM, Beima-Sofieaohamed ZH, et al. Long-acting injectable antiretroviral treatment acceptability and preferences:a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV[J]. AIDS Patient Care STDS, 2019, 33(3):104-111. DOI:10.1089/apc.2018.0198.
• [12]Christopoulos KA, Smith MB, Pareek P, et al. Learning from the first:a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics[J]. J Int AIDS Soc, 2024,27(11):e26394. DOI:10.1002/jia2.26394.
• [13]Carillon S, Laborde-Balen G, Diop M, et al. Implementing long-acting injectable antiretroviral treatments in Senegal:issues, challenges and conditions for introducing them.Qualitative study with healthcare providers and patients[J].AIDS Care, 2024, 36(5):703-709. DOI:10.1080/09540121.2023.2253506.
• [14]Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART:a qualitative study among PLHIV participating in a Phase II study of cabotegravir+rilpivirine(LATTE-2)in the United States and Spain[J]. PLoS One,2018, 13(1):e0190487. DOI:10.1371/journal.pone.0190487.
• [15]Thorp M, Phiri S, Phiri K, et al. Brief report:stated preferences for long-acting injectable ART among mobile men living with HIV in Malawi:a qualitative study[J]. J Acquir Immune Defic Syndr, 2024, 97(5):e25-e29. DOI:10.1097/QAI.0000000000003525.
• [16]Chayama KL, Ng C, Brohman I, et al. Acceptability of longacting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada:a qualitative study[J]. PLoS One, 2025, 20(2):e0319010. DOI:10.1371/journal.pone.0319010.
• [17]Rutstein SE, Sibley AL, Huffstetler HE, et al. Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam:a qualitative study[J]. Lancet Reg Health West Pac, 2023, 31:100603.DOI:10.1016/j.lanwpc.2022.100603.
• [18]Rodriguez Gonzalez H, Volcan AI, Castonguay BJU, et al.“What is the benefit?”:perceptions and preferences for longacting injectable antiretroviral therapy among people living with HIV[J]. AIDS Educ Prev, 2023, 35(6):467-483. DOI:10.1521/aeap.2023.35.6.467.
• [19]Ekusai-Sebatta D, Agnes Odongpiny EL, Kiragga AN, et al.“Injectable ARVs will give me peace” women’s acceptability of injectable antiretroviral therapy in prevention of HIV vertical transmission in Uganda[J]. Sci Rep, 2025, 15(1):25818.DOI:10.1038/s41598-025-10686-8.
• [20]Agarwal H, Huffstetler HE, Lopez C, et al.“I feel like I don’t even have HIV anymore”:facilitators, barriers, and experience regarding use of long-acting injectable antiretroviral therapy among persons with HIV in north Carolina[J]. AIDS Patient Care Stds, 2024, 38(7):324-329. DOI:10.1089/apc. 2024.0076.
• [21]Chounta V, Overton ET, Mills A, et al. Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or8 weeks(ATLAS-2M)[J]. Patient, 2021, 14(6):849-862.DOI:10.1007/s40271-021-00524-0.
• [22]Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Longacting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection(LATTE-2):96-week results of a randomised,open-label, phase 2b, non-inferiority trial[J]. Lancet, 2017,390(10101):1499-1510. DOI:10.1016/S0140-6736(17)31917-7.
• [23]Smith GHR, Henry WK, Podzamczer D, et al. Efficacy,safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection:5-year results from the LATTE-2 study[J]. Open Forum Infect Dis, 2021, 8(9):ofab439. DOI:10.1093/ofid/ofab439.
• [24]de los Rios P, Okoli C, Castellanos E, et al. Physical,emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life:findings from the positive perspectives study[J].AIDS Behav, 2021, 25(3):961-972. DOI:10.1007/s10461-020-03055-1.
• [25]Gagliardini R, De Benedittis S, Tavelli A, et al. Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV:real-life data from the Icona Cohort[J]. J Antimicrob Chemother, 2025, 80(8):2169-2178. DOI:10.1093/jac/dkaf184.
• [26]孟晓军，陈积标，尹寒露，等.男男性行为者HIV长效注射暴露前预防用药意愿及相关因素分析[J].中国艾滋病性病，2025,31(1):70-74.DOI:10.13419/j.cnki.aids.2025.01.11.
• [27]Edwards GG, Miyashita-Ochoa A, Castillo EG, et al. Longacting injectable therapy for people with HIV:looking ahead with lessons from psychiatry and addiction medicine[J]. AIDS Behav, 2023, 27(1):10-24. DOI:10.1007/s10461-022-03817-z.
• [28]Cocohoba J, Cuca Y, Sherman E, et al. Preparing for pharmacy-based delivery of long-acting injectable antiretrovirals:a pre-implementation study[J]. BMC Health Serv Res, 2025, 25(1):808. DOI:10.1186/s12913-025-12971-8.
• [29]Nachega JB, Scarsi KK, Gandhi M, et al. Long-acting antiretrovirals and HIV treatment adherence[J]. Lancet HIV,2023, 10(5):e332-e342. DOI:10.1016/S2352-3018(23)00051-6.
• [30]朱彪，何玲玲.抗人类免疫缺陷病毒药物的新进展[J].浙江医学，2025, 47(9):897-902.
• [31]Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus(HIV)in high-income countries[J]. Clin Infect Dis, 2022, 75(Suppl 4):S541-S548.DOI:10.1093/cid/ciac716.
• [32]Koester KA, Colasanti JA, McNulty MC, et al. Assessing readiness to implement long-acting injectable HIV antiretroviral therapy:provider and staff perspectives[J]. Implement Sci Commun, 2023, 4(1):128. DOI:10.1186/s43058-023-00506-3.
• [33]McCrimmon T, Collins LF, Perez-Brumer A, et al. Longacting injectable antiretrovirals for HIV treatment:a multi-site qualitative study of clinic-level barriers to implementation in the United States[J]. AIDS Patient Care STDS, 2024, 38(2):61-69. DOI:10.1089/apc.2023.0248.
• [34]O’Shea JG, Cholli P, Heil EL, et al. Considerations for longacting antiretroviral therapy in older persons with HIV[J].Aids, 2023, 37(15):2271-2286. DOI:10.1097/qad.0000000000003704.
• [35]李凌华，蔡琳，陈雅红，等.长效抗HIV药物临床应用专家共识[J].中国艾滋病性病，2024,30(12):1230-1239.DOI:10.13419/j.cnki.aids.2024.12.01.